Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD) (PHENIX)
Epidemiological Study to Assess the Symptom Patterns and Management Strategies in Patients Consulting With Persistent GERD Symptoms in Primary Care
Sponsor: AstraZeneca
Listed as NCT00768443, this observational or N/A phase trial focuses on Gastroesophageal Reflux Disease and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bjelovar, Croatia , Bulinec, Croatia , Crikvenica, Croatia , Daruvar, Croatia , Delnice, Croatia , Garešnica, Croatia , Gospić, Croatia , Ivanec, Croatia , Kalnik, Croatia , Karlovac, Croatia and 22 more locations